Showing 1 to 12 of 15 results
Lower-Cost HIV Prevention Drug to Reach Millions
A new, injectable HIV prevention drug, Lenacapavir, will be made available at a drastically reduced cost of $40 per year in over 120 low- and middle-income countries by 2027, potentially impacting millions and accelerating efforts to curb the HIV/AIDS epidemic.
Lower-Cost HIV Prevention Drug to Reach Millions
A new, injectable HIV prevention drug, Lenacapavir, will be made available at a drastically reduced cost of $40 per year in over 120 low- and middle-income countries by 2027, potentially impacting millions and accelerating efforts to curb the HIV/AIDS epidemic.
Progress
28% Bias Score
EU Approves Twice-Yearly HIV Prevention Injection
European regulators approved Gilead's lenacapavir, a twice-yearly HIV prevention injection, 100% effective in trials, offering a significant advancement amid rising HIV cases (24,700 new diagnoses in 2023, up 11.8% from 2022).
EU Approves Twice-Yearly HIV Prevention Injection
European regulators approved Gilead's lenacapavir, a twice-yearly HIV prevention injection, 100% effective in trials, offering a significant advancement amid rising HIV cases (24,700 new diagnoses in 2023, up 11.8% from 2022).
Progress
40% Bias Score
Lenacapavir's Promise vs. US Cuts: A Critical Juncture for HIV Eradication
Lenacapavir, a once-yearly HIV injection, demonstrates near-perfect efficacy in preventing new infections (0% in trials) and slashing acquisition risk by 96%, but US cuts to infectious disease programs threaten to hinder global eradication efforts despite Egypt's successful hepatitis C eradication s...
Lenacapavir's Promise vs. US Cuts: A Critical Juncture for HIV Eradication
Lenacapavir, a once-yearly HIV injection, demonstrates near-perfect efficacy in preventing new infections (0% in trials) and slashing acquisition risk by 96%, but US cuts to infectious disease programs threaten to hinder global eradication efforts despite Egypt's successful hepatitis C eradication s...
Progress
56% Bias Score
Annual HIV-Prevention Injection Shows Promise in Phase 1 Trial
A phase 1 trial showed a single intramuscular injection of lenacapavir provided effective HIV prevention for at least 56 weeks in 40 participants, potentially revolutionizing PrEP access and adherence, with a semiannual version under regulatory review.
Annual HIV-Prevention Injection Shows Promise in Phase 1 Trial
A phase 1 trial showed a single intramuscular injection of lenacapavir provided effective HIV prevention for at least 56 weeks in 40 participants, potentially revolutionizing PrEP access and adherence, with a semiannual version under regulatory review.
Progress
44% Bias Score
Lenacapavir: A Breakthrough HIV Drug Faces Access Challenges
A new injectable HIV drug, Lenacapavir, demonstrated a 96% reduction in infection risk in clinical trials, leading Science magazine to name it 'Discovery of the Year' for 2024; however, global access is hindered by high costs and limited distribution agreements.
Lenacapavir: A Breakthrough HIV Drug Faces Access Challenges
A new injectable HIV drug, Lenacapavir, demonstrated a 96% reduction in infection risk in clinical trials, leading Science magazine to name it 'Discovery of the Year' for 2024; however, global access is hindered by high costs and limited distribution agreements.
Progress
44% Bias Score
Lenacapavir: Six-Monthly HIV Prevention Injection Named "Science" Breakthrough of the Year
"Science" magazine selected Lenacapavir, a six-monthly HIV-prevention injection, as its 2024 Breakthrough of the Year due to its superior efficacy and convenience compared to daily pills, potentially impacting global HIV prevention efforts.
Lenacapavir: Six-Monthly HIV Prevention Injection Named "Science" Breakthrough of the Year
"Science" magazine selected Lenacapavir, a six-monthly HIV-prevention injection, as its 2024 Breakthrough of the Year due to its superior efficacy and convenience compared to daily pills, potentially impacting global HIV prevention efforts.
Progress
36% Bias Score
US to Invest in New HIV Prevention Drug
The U.S. will invest in lenacapavir, a new HIV prevention drug, aiming to reach 2 million people in three years, prioritizing pregnant and breastfeeding mothers in high-burden countries to prevent mother-to-child transmission.
US to Invest in New HIV Prevention Drug
The U.S. will invest in lenacapavir, a new HIV prevention drug, aiming to reach 2 million people in three years, prioritizing pregnant and breastfeeding mothers in high-burden countries to prevent mother-to-child transmission.
Progress
20% Bias Score
FDA Approves Twice-Yearly Injectable HIV Prevention Treatment
The FDA approved Yeztugo, Gilead's new twice-yearly injectable HIV prevention treatment, on June 18, 2025, showing over 99.9% efficacy in clinical trials involving over 4,000 participants across diverse populations, but concerns remain about its high potential cost.
FDA Approves Twice-Yearly Injectable HIV Prevention Treatment
The FDA approved Yeztugo, Gilead's new twice-yearly injectable HIV prevention treatment, on June 18, 2025, showing over 99.9% efficacy in clinical trials involving over 4,000 participants across diverse populations, but concerns remain about its high potential cost.
Progress
52% Bias Score
Annual Lenacapavir Injection Shows Promise in HIV Prevention
A phase 1 study shows that a single annual injection of lenacapavir, an HIV antiviral drug, resulted in blood concentrations sufficient to potentially prevent HIV infection, offering a promising new approach to prevention.
Annual Lenacapavir Injection Shows Promise in HIV Prevention
A phase 1 study shows that a single annual injection of lenacapavir, an HIV antiviral drug, resulted in blood concentrations sufficient to potentially prevent HIV infection, offering a promising new approach to prevention.
Progress
44% Bias Score
Lenacapavir: 99.9% Effective HIV Prevention in Clinical Trials
Lenacapavir, a new HIV drug, demonstrated 99.9% effectiveness in preventing infection in a recent study of over 2,000 participants across diverse genders, representing a significant advancement in PrEP and potentially revolutionizing HIV prevention strategies.
Lenacapavir: 99.9% Effective HIV Prevention in Clinical Trials
Lenacapavir, a new HIV drug, demonstrated 99.9% effectiveness in preventing infection in a recent study of over 2,000 participants across diverse genders, representing a significant advancement in PrEP and potentially revolutionizing HIV prevention strategies.
Progress
48% Bias Score
Lenacapavir: Science's 2024 Breakthrough in HIV Prevention
Science magazine named the injectable HIV prevention drug lenacapavir its 2024 breakthrough; 99.9% effective in preventing HIV in clinical trials among men who have sex with men and transgender individuals, offering a six-month dosage alternative to daily oral PrEP, pending FDA (2025) and European a...
Lenacapavir: Science's 2024 Breakthrough in HIV Prevention
Science magazine named the injectable HIV prevention drug lenacapavir its 2024 breakthrough; 99.9% effective in preventing HIV in clinical trials among men who have sex with men and transgender individuals, offering a six-month dosage alternative to daily oral PrEP, pending FDA (2025) and European a...
Progress
32% Bias Score
Lenacapavir: A Breakthrough in HIV Prevention
Two large clinical trials showed lenacapavir, a twice-yearly injection, to be 96–100% effective in preventing HIV, exceeding daily oral PrEP's real-world effectiveness; this breakthrough could significantly curb the global HIV epidemic, though access challenges remain.
Lenacapavir: A Breakthrough in HIV Prevention
Two large clinical trials showed lenacapavir, a twice-yearly injection, to be 96–100% effective in preventing HIV, exceeding daily oral PrEP's real-world effectiveness; this breakthrough could significantly curb the global HIV epidemic, though access challenges remain.
Progress
52% Bias Score
Showing 1 to 12 of 15 results